Plain english summary
Introduction
Rationale
Clinician – reported outcome measures |
---|
1. Fistula healing (clinical and radiological) |
2. New fistula or abscess |
3. Need for rescue intervention (minor or major) |
Patient – reported outcome measures |
---|
4. Pain related to fistula and surrounding area |
5. Global assessment of continence |
6. Impact on quality of life of fistula discharge |
7. Global quality of life assessment |
Objectives
Methods
Eligibility criteria
Information sources
Search strategy
Data collection process
Data items
Study risk of bias assessment
Measurement properties
Synthesis methods
Certainty assessment
Results
Study selection
Study characteristics
OMI characteristics
n | KEY PAPER | Core outcomes assessed | |
---|---|---|---|
ClinROMs (Clinician reported outcome measures) | |||
Cleveland Clinic Foundation Pelvic Pouch Questionnaire (CCFPPQ) | 3 | Kirat et al. [36] | Global assessment of continence Impact on quality of life of fistula discharge Global quality of life assessment |
Oresland pouch function (OPF) | 1 | Oresland et al. [1] | Global assessment of continence Impact on quality of life of fistula discharge Global quality of life assessment |
Pouchitis Disease Activity Index (PouchitisDAI) | 5 | Sandborn et al. [2] | Fistula healing |
modified Pouchitis disease activity index (mPDAI) | 1 | Shen et al. [21] | Fistula healing |
Perianal Disease Activity Index (PDAI) | 1 | Irvine [37] | Fistula healing |
PROMs (Patient reported outcome measures) | |||
Jorge & Wexner incontinence grading score (WI) | 1 | Jorge and Wexner [33] | Global assessment of continence |
Cleveland Global Quality of Life Score (CGQL) | 5 | Fazio et al. [38] | Global quality of life assessment |
Gastrointestinal Quality of Life Index (GIQL) | 1 | Eypasch et al. [34] | Global quality of life assessment |
Inflammatory Bowel Disease Questionnaire (IBDQ) | 2 | Guyatt et al. [30] | Global quality of life assessment |
Short Form 36 (SF-36) | 1 | Ware et al. [31] | Global quality of life assessment |
Pouch specific ClinROMs or PROMs | |||
Pouch Functional Score (PFS) | 0 | Lovegrove et al. [39] | Need for rescue intervention Global assessment of continence |
Ileoanal Pouch Syndrome Severity Score (IPSSS) | 0 | Cavallaro et al. [32] | Global assessment of continence Global quality of life assessment |
Pouch Dysfunction Score (PDS) | 0 | Brandsborg [40] | Global assessment of continence |
Characteristics of individual PROMS
The characteristics of the 13 OMIs used in studies on pouch fistulae are outlined in Table 3
OMI* (reference to first article) | Construct(s) | Target population | Mode of administration (e.g. self-report, interview-based, parent/proxy report etc.) | Recall period | (Sub)scale (s) (number of items) | Response options | Range of scores/scoring | Original language | Available translations | Patient involvement in development study |
---|---|---|---|---|---|---|---|---|---|---|
ClinROMs | ||||||||||
CCFPPQ | Pouch Function | IPAA | Self-reported | NA | 9 | Bowel frequency (number of bowel movements per 24 h), urgency (inability to defer bowel movements for more than 15 min), faecal incontinence (inadvertent passage of liquid or solid stool), stool seepage (soiling during day or night), use of pads, and dietary, social, work, and sexual restrictions | Continuous | English | English | No |
OPF | Pouch Function | IPAA | Self-reported | 2 Weeks/ Bowel diary | 9 | Bowel frequency (day/night), Urgency, Evacuation difficulties, Soiling/Seepage, Perianal soreness, Protective pad, Dietary restrictions, Medication, Social handicap | 0 (Good function) - 15 (Poor function) | Swedish | English | No |
PouchitisDAI | Pouchitis | IPAA | Clinician | NA | 7 | Clinical/Endoscopic inflammation/Histological inflammation | 0 - 18 (> 7 defined as clinically significant pouchitis) | English | English | No |
mPDAI | Pouchitis | IPAA | Clinician | NA | 6 | Clinical and Endoscopic | 0 - 12 (> 5 as clinically significant) | English | English | No |
PDAI | Perianal Crohn's disease | pCD | Self-reported/ Clinician | NA | 5 | Discharge, Pain, Restriction of sexual activity, Type of perianal disease, Degree of induration | 0 (No disease)- 20 (Severe) | English | English | No |
PROMs | ||||||||||
WI | Incontinence | All patients | Self-reported | NA | 5 | Solid, Liquid, Gas, Wears pad, Lifestyle alteration | 0 (Perfect continence)- 20 (Complete incontinence) | English | 42 translations | No |
CGQL | QOL | Post- IPAA | Self-reported | NA | 3 | Quality of Life, Quality of Health, Energy Level | 0 - 1 (Perfect QOL) | English | English, Italian | No |
GIQLI | QOL | GI Disease | Self-reported | 2 Weeks | 36 | Subjective GI QOL | 0 - 144 (perfect QOL) | German | English | Yes |
IBDQ | QOL | IBD | Self-reported | 4 weeks | 32 | IBD QOL: bowel symptoms, systemic symptoms, emotional function, social function | 32 (worst) - 244 (Perfect quality) | English | 127 translations | Yes |
SF-36 | QOL | All patients | Self-reported | 4 weeks | 36 | Functional status, Wellbeing, Overall evaluation of health | 0 (Worst) - 100 (Best) | English | 193 translations | Yes |
Pouch specific ClinROMs or PROMs | ||||||||||
PFS | Pouch Function | IPAA | Self-reported | NA | 7 | 24H Stool frequency, Nocturnal stool frequency, Urgency, Major incontinence, Minor incontinence, Antidiarrhoeals, Antibiotics | 0 - 30 (Worse score) | English | English | No |
IPSSS | Pouch function | IPAA | Self-reported | NA | 3 | 3 Domains: 15 questions | 0 - 145 | English | English | Yes |
PDS | Pouch dysfunction | IPAA | Self-reported | 2 Weeks | 6 | 5 Domains, 1 QOL | 0 - 7.5 | Danish | English | No |
Interpretability and feasibility of OMI
COSMIN appraisal of OMI development
OMI | PROM design | Cognitive interview (CI) study2 | TOTAL PROM DEVELOPMENT | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General design requirements | Concept elicitation1 | Total PROM design | General design requirements | Comprehensibility | Total CI study | ||||||||
Reference | Language in which the PROM was developed | Clear construct | Clear origin of construct | Clear target population for which the PROM was developed | Clear context of use | PROM developed in sample representing the target population | CI study performed in sample representing the target population | ||||||
Fazio et al. [28] | CCFPPQ | English | V | D | V | V | A | I | I | I | I | ||
Oresland et al. [1] | OPF | English, Swedish | V | D | V | V | A | I | I | I | I | ||
Sandborn et al. [2] | PouchitisDAI | English | V | V | V | V | A | A | A | I | I | ||
Shen et al. [21] | mPDAI | English | V | V | V | V | V | A | A | I | I | ||
Irvine [37] | PDAI | English | V | V | V | V | V | D | D | V | D | D | D |
Jorge and Wexner [33] | WI | English | V | V | V | V | A | D | D | I | I | ||
Fazio et al. [38] | CGQL | English | V | V | V | V | D | D | D | I | I | ||
Eypasch et al. [34] | GIQLI | English | V | V | V | V | V | D | D | V | V | D | D |
Guyatt et al. [30] | IBDQ | English | V | V | V | V | V | D | D | V | V | D | D |
Ware et al. [31] | SF-36 | English | V | V | V | V | V | D | D | V | V | A | D |
Lovegrove et al. 39 | PFS | English | V | V | V | V | V | A | A | I | I | ||
Cavallaro et al. [32] | IPSSS | English | V | V | V | V | V | A | A | V | V | A | A |
Brandsborg et al. [40 ] | PDS | English | V | V | V | V | V | D | D | V | V | D | D |
COSMIN Assessment of measurement properties of OMIs (Table 5)
CCFPPQ | OPF | PouchitisDAI | mPDAI | PDAI | WI | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | |
+ /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | |
Content validity | ? | ? | +/− | Low | +/− | Low | +/− | Moderate | +/− | Moderate | ||
Relevance | ? | +/− | Very low | + | Low | + | Low | + | Moderate | + | Moderate | |
Comprehensiveness | ? | - | Very low | - | Low | - | Low | ? | - | Moderate | ||
Comprehensibility | ? | ? | + | Low | + | Low | + | Moderate | + | Moderate | ||
Structural validity | ? | ? | ? | ? | ? | ? | ||||||
Internal consistency | ? | ? | ? | ? | ? | + | Moderate | |||||
Cross-cultural validity | ? | ? | ? | ? | + | Moderate | + | Moderate | ||||
Measurement invariance | ? | ? | ? | ? | ? | ? | ||||||
Reliability | ? | ? | ? | ? | - | Moderate | + | Moderate | ||||
Measurement error | ? | ? | ? | ? | ? | ? | ||||||
Criterion validity | ? | ? | + | Low | + | Low | + | Moderate | ? | |||
Construct validity | ? | ? | + | Low | + | Low | + | Moderate | + | Moderate | ||
Responsiveness | ? | ? | ? | + | Low | + | Moderate | ? |
CGQL | GIQLI | IBDQ | SF-36 | |||||
---|---|---|---|---|---|---|---|---|
OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | |
+ /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | |
Content validity | +/− | Low | +/− | Moderate | + | Moderate | +/− | Moderate |
Relevance | +/− | Low | + | Moderate | + | Moderate | + | Moderate |
Comprehensiveness | ? | ? | + / − | Moderate | - | Moderate | ||
Comprehensibility | + | Low | ? | + | Moderate | +/− | Moderate | |
Structural validity | ? | + | Moderate | ? | + | Moderate | ||
Internal consistency | + | Low | + | Moderate | + | Moderate | + | Moderate |
Cross-cultural validity | + | Low | + | Moderate | + | Moderate | + | Moderate |
Measurement invariance | ? | ? | ? | ? | ||||
Reliability | + | Low | + | Moderate | + | Moderate | + | Moderate |
Measurement error | ? | ? | ? | + | Moderate | |||
Criterion validity | ? | ? | ? | ? | ||||
Construct validity | + | Low | + | Moderate | + | Moderate | + | Moderate |
Responsiveness | + | Low | + | Moderate | + | Moderate | ? | |
GIQLI upgraded in view of multiple + measurement properties | IBDQ upgraded to moderate as multiple validation studies | SF-36 upgraded to moderate as multiple validation studies |
PFS | IPSSS | PDS | ||||
---|---|---|---|---|---|---|
OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | OVERALL RATING | QUALITY OF EVIDENCE | |
+ /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | + /− /? | High, moderate, low, very low | |
Content validity | +/− | Low | + | Moderate | +/− | Low |
Relevance | + | Low | + | Moderate | + | Low |
Comprehensiveness | - | Low | + | Moderate | +/− | Low |
Comprehensibility | ? | + | Moderate | + | Low | |
Structural validity | ? | ? | ? | |||
Internal consistency | ? | ? | ? | |||
Cross-cultural validity | ? | + | Moderate | ? | ||
Measurement invariance | ? | ? | ? | |||
Reliability | ? | + | Moderate | + | Low | |
Measurement error | ? | ? | ? | |||
Criterion validity | ? | + | Moderate | + | Low | |
Construct validity | ? | + | Moderate | ? | ||
Responsiveness | ? | ? | ? | |||
IPSSS downgraded to moderate in view of limited measurement properties |
Content validity (assessed separately as per COSMIN guidelines)
Remaining measurement properties
COSMIN risk of bias in studies (Table 6) and quality of the evidence for measurement properties (Table 5)
PROM | Content validity | Structural validity | Internal consistency | Cross-cultural validity | Reliability | Measurement error | Criterion validity | Construct validity | Responsiveness | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Asking patients | Asking experts | ||||||||||||||||||
Relevance | Comprehensiveness | Comprehensibility | Relevance | Comprehensiveness | Convergent validity | Known groups validity | Comparison with gold standard | Comparison with other instruments | Comparison between subgroups | Comparison before and after intervention | |||||||||
CCFPPQ | D | D | D | A | A | ||||||||||||||
OPF | |||||||||||||||||||
PouchitisDAI | D | D | I | A | |||||||||||||||
mPDAI | D | D | A | A | A | A | |||||||||||||
PDAI | D | D | D | A | A | I | I | I | A | I | I | I | I | I | A | I | A | ||
WI | D | D | |||||||||||||||||
CGQL | D | D | V | A | |||||||||||||||
GIQLI | D | D | D | D | D | D | D | I | D | A | |||||||||
IBDQ | D | D | D | D | D | I | I | V | |||||||||||
SF-36 | A | A | A | A | A | V | A | A | V | I | D | ||||||||
PFS | I | D | I | ||||||||||||||||
IPSSS | D | D | A | V | V | A | V | D | V | ||||||||||
PDS | D | D | D | D | D | V | V |